Common toxicities of mammalian target of rapamycin inhibitors

Targeted Oncology

Volumn 6, Issue 2, 2011, Pages 125-129

  Soefje, Scott A ^a   Karnad, Anand ^a   Brenner, Andrew J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Everolimus; mTOR inhibitors; Radaforolimus; Temsirolmus; Toxicity

Indexed keywords

AMIFOSTINE; ANTIOXIDANT; BENZOYL PEROXIDE; CARNOSINE; CLINDAMYCIN; CLOBETASOL; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN; EVEROLIMUS; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MINOCYCLINE; RAPAMYCIN; RETINOIC ACID; RIDAFOROLIMUS; TEMSIROLIMUS;

ANEMIA; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; DIARRHEA; DRUG ERUPTION; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INCIDENCE; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TOXICITY; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79960613394     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0174-9     Document Type: Review

References (25)

1. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
2. E Raymond J Alexandre S Faivre, et al. 2004 Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2336 2347 15136596 10.1200/JCO.2004.08.116 1:CAS:528:DC%2BD2cXpsVWltbc%3D (Pubitemid 41115390)
3. MB Atkins M Hildalgo WM Stadler, et al. 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918 14990647 10.1200/JCO.2004.08.185 1:CAS:528:DC%2BD2cXpsVKisr0%3D (Pubitemid 41103603)
4. RJ Motzer B Escudier S Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
5. A O'Donnell S Faivre HA Burris III, et al. 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 1588 1595 18332470 10.1200/JCO.2007.14.0988
6. CM Hartford L Berk JW Loewry, et al. 2009 A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies Clin Cancer Res 15 1428 1434 19228743 10.1158/1078-0432.CCR-08-2076 1:CAS:528:DC%2BD1MXitVOktL8%3D
7. MM Mita AC Mita QS Chu, et al. 2008 Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 361 367 18202410 10.1200/JCO.2007.12.0345 1:CAS:528:DC%2BD1cXitVGntLk%3D (Pubitemid 351171685)
8. E Mahe E Morelon S Lechaton, et al. 2005 Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy Transplantation 79 476 482 15729175 10.1097/01.TP.0000151630.25127.3A 1:CAS:528: DC%2BD2MXhsF2lt7s%3D (Pubitemid 40280181)
9. S Sonis N Treister S Chawla G Demetri F Haluska 2010 Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients Cancer 116 210 215 19862817 1:CAS:528: DC%2BC3cXitFGiurw%3D
10. JM Campistol JW de Fijter SM Flechner, et al. 2010 mTOR inhibitor-associated dermatologic and mucosal problems Clin Transplant 24 149 156 20236129 10.1111/j.1399-0012.2010.01232.x 1:CAS:528:DC%2BC3cXmtVSrsLs%3D
11. M Fouladi F Lanningham J Wu, et al. 2007 Phase I study of everolimus in pediatric patients with refractory solid tumors J Clin Oncol 25 4806 4812 17947729 10.1200/JCO.2007.11.4017 1:CAS:528:DC%2BD2sXhtlCgsLbE (Pubitemid 350086485)
12. P Chuang AJ Langone 2007 Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus Am J Transplant 7 714 717 17250555 10.1111/j.1600-6143.2006.01678.x 1:CAS:528:DC%2BD2sXjvFOhtLg%3D (Pubitemid 46376460)
13. E Morelon M Stern D Israël-Biet, et al. 2001 Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients Transplantation 72 787 790 11571438 10.1097/00007890-200109150-00008 1:STN:280:DC%2BD3MritlGjug%3D%3D (Pubitemid 32879846)
14. PT Pham PC Pham GM Danovitch, et al. 2004 Sirolimus-associated pulmonary toxicity Transplantation 77 1215 1220 15114088 10.1097/01.TP.0000118413.92211.B6 1:CAS:528:DC%2BD2cXksFOkuro%3D (Pubitemid 38580300)
15. I Duran LL Sui AM Oza, et al. 2004 Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 42 1875 1880 10.1016/j.ejca.2006.03.015
16. G Aparicio MB Calvo V Medina, et al. 2009 Comprehensive lung injury pathology induced by mTOR inhibitors Clin Transl Oncol 11 499 510 19661024 10.1007/s12094-009-0394-y 1:CAS:528:DC%2BD1MXhtVygsLzO
17. E Galanis JC Buckner MJ Maurer, et al. 2005 Phase II trial of temsirolimus (CCI-779) in recurrent Glioblastoma Multiforme: a north central cancer treatment group study J Clin Oncol 23 5294 5304 15998902 10.1200/JCO.2005.23.622 1:CAS:528:DC%2BD2MXpslOrtLw%3D (Pubitemid 46206983)
18. L Beretta AC Gingras YV Svitkin, et al. 1996 Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation EMBO J 15 658 664 8599949 1:CAS:528:DyaK28XhsV2gt7s%3D (Pubitemid 26044579)
19. C Taha Z Liu J Jin, et al. 1999 Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin J Biol Chem 274 46 33085 33091 10551878 10.1074/jbc.274.46.33085 1:CAS:528:DyaK1MXntlygu7g%3D
20. DA Rizzieri E Feldman JF DiPersio, et al. 2008 A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 14 2756 2762 18451242 10.1158/1078-0432.CCR-07-1372 1:CAS:528:DC%2BD1cXlsV2qurs%3D
21. Executive Summary: Standards of Medical Care in Diabetes-2011. Diabetes Care 34:S4-S10
22. C Brattstrom H Wilczek G Tyden, et al. 1998 Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin) Transplantation 65 1272 1274 9603181 10.1097/00007890-199805150-00023 1:CAS:528:DyaK1cXjslSms78%3D (Pubitemid 28224351)
23. A Gaasbeek AE Meinders 2005 Hypophosphatemia: an update on its etiology and treatment Am J Med 118 1094 1101 16194637 10.1016/j.amjmed.2005.02.014 1:CAS:528:DC%2BD2MXhtVGrs7nP (Pubitemid 41362606)
24. Torisel (2010) Package insert. Wyeth Pharmaceuticals, Philadelphia
25. Afinitor (2010) Package insert. Novartis Pharmaceuticals Corporation, East Hanover